Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market

Having made a strong start with sales of over $120m in its first six months on the market, Coherus believes its Udenyca biosimilar could end 2019 with more than a fifth of the US pegfilgrastim market by volume.

PieChart
Coherus believes its Udenyca biosimilar can take at least 20% of the US pegfilgrastim market by the end of this year • Source: Shutterstock

Coherus BioSciences believes it can capture at least a fifth of the US pegfilgrastim market by the end of 2019, having launched its Udencya (pegfilgrastim-cbqv) brand at the start of this year as the second biosimilar, around six months after Mylan introduced Fulphila (pegfilgrastim-jmdb) as the first rival to Amgen’s Neulasta reference biologic. The US-based biosimilars specialist, which is now turning a profit, said it ended June with a 13% unit market share.

“After just two quarters on the market, Udenyca is the US market-leading pegfilgrastim biosimilar, with greater than approximately 13% of...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.